Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Bought by BNP Paribas Financial Markets

BNP Paribas Financial Markets raised its holdings in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 1,589.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 76,154 shares of the company's stock after purchasing an additional 71,647 shares during the quarter. BNP Paribas Financial Markets owned 0.14% of Stoke Therapeutics worth $936,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Charles Schwab Investment Management Inc. lifted its position in shares of Stoke Therapeutics by 9.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 316,134 shares of the company's stock worth $3,885,000 after purchasing an additional 26,870 shares during the last quarter. Intech Investment Management LLC bought a new stake in shares of Stoke Therapeutics during the third quarter worth $160,000. Los Angeles Capital Management LLC lifted its position in shares of Stoke Therapeutics by 54.3% during the third quarter. Los Angeles Capital Management LLC now owns 103,005 shares of the company's stock worth $1,266,000 after purchasing an additional 36,240 shares during the last quarter. Mesirow Financial Investment Management Inc. bought a new stake in shares of Stoke Therapeutics during the third quarter worth $192,000. Finally, Healthcare of Ontario Pension Plan Trust Fund lifted its position in shares of Stoke Therapeutics by 426.1% during the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,387,200 shares of the company's stock worth $18,741,000 after purchasing an additional 1,123,500 shares during the last quarter.

Stoke Therapeutics Stock Performance

STOK traded down $0.28 on Wednesday, hitting $12.98. The company had a trading volume of 283,002 shares, compared to its average volume of 748,445. The stock has a fifty day moving average price of $12.46 and a 200-day moving average price of $13.68. Stoke Therapeutics, Inc. has a 12-month low of $4.09 and a 12-month high of $17.58. The stock has a market capitalization of $687.55 million, a price-to-earnings ratio of -6.15 and a beta of 0.95.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.47) earnings per share for the quarter, topping analysts' consensus estimates of ($0.52) by $0.05. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The business had revenue of $4.89 million for the quarter, compared to analyst estimates of $3.46 million. Analysts forecast that Stoke Therapeutics, Inc. will post -2.03 EPS for the current fiscal year.

Insider Transactions at Stoke Therapeutics

In related news, major shareholder Skorpios Trust sold 1,937,500 shares of Stoke Therapeutics stock in a transaction dated Thursday, September 19th. The stock was sold at an average price of $14.05, for a total transaction of $27,221,875.00. Following the completion of the sale, the insider now owns 8,906,181 shares of the company's stock, valued at $125,131,843.05. The trade was a 17.87 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Barry Ticho sold 10,000 shares of Stoke Therapeutics stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $12.07, for a total value of $120,700.00. Following the sale, the insider now directly owns 51,277 shares of the company's stock, valued at $618,913.39. This trade represents a 16.32 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 2,000,349 shares of company stock worth $28,031,296. Insiders own 11.30% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Needham & Company LLC restated a "buy" rating and set a $22.00 price target on shares of Stoke Therapeutics in a research note on Wednesday, November 6th. Leerink Partnrs upgraded Stoke Therapeutics to a "strong-buy" rating in a research note on Friday, October 11th. HC Wainwright restated a "buy" rating and set a $35.00 price target on shares of Stoke Therapeutics in a research note on Wednesday, November 6th. Leerink Partners assumed coverage on Stoke Therapeutics in a research note on Monday, October 14th. They set an "outperform" rating and a $18.00 price target on the stock. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Stoke Therapeutics in a research note on Tuesday. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $20.83.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.